Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancer

Cancer Cell International
Aysha M AljaberiSally P Wheatley

Abstract

Survivin is a protein that is normally present only in G2 and M-phases in somatic cells, however, in cancer cells, it is expressed throughout the cell cycle. A prosurvival factor, survivin is both an inhibitor of apoptosis and an essential mitotic protein, thus it has attracted much attention as a target for new oncotherapies. Despite its prevalence in cancer, reports of survivin mutations have mostly been restricted to loci within its promoter, which increase the abundance of the protein. To date the only published mutation within the coding sequence is an adenine > guanine substitution in exon 4. This polymorphism, which was found in a cohort of Korean lung cancer patients, causes a lysine > glutamic acid mutation (K129E) in the protein. However, whether it plays a causative role in cancer has not been addressed. Using site directed mutagenesis we recapitulate K129E expression in cultured human cells and assess its anti-apoptotic and mitotic activities. K129E retains its anti-apoptotic activity, but causes errors in mitosis and cytokinesis, which may be linked to its reduced affinity for borealin. K129E expression can induce genomic instability by introducing mitotic aberrations, thus it may play a causative role in cancer.

References

Dec 2, 1999·Nature Genetics·V E VelculescuK W Kinzler
Jul 6, 2000·Nature Structural Biology·M A VerdeciaJ P Noel
Nov 21, 2001·The Journal of Biological Chemistry·William H HoffmanMaureen Murphy
Jun 5, 2003·Journal of Cell Science·Ana CarvalhoSally P Wheatley
Sep 25, 2003·Cell Cycle·Susanne M A Lens, René H Medema
Jul 21, 2004·Journal of Computational Chemistry·Eric F PettersenThomas E Ferrin
Jun 21, 2005·Journal of Cellular and Molecular Medicine·Nadia ZaffaroniMaria Grazia Daidone
Jun 14, 2006·The Journal of Cell Biology·Gerben VaderSusanne M A Lens
Sep 5, 2006·The Journal of Biological Chemistry·Rita ColnaghiSally P Wheatley
Apr 26, 2007·Cell Cycle·Sally P WheatleySusanne M A Lens
Jul 10, 2007·Cancer Research·Roland H StauberShirley K Knauer
Sep 13, 2007·Nature Reviews. Molecular Cell Biology·Sandrine RuchaudWilliam C Earnshaw
Oct 27, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jin Sung JangJae Yong Park
Dec 7, 2007·The Journal of Biological Chemistry·Claire M ConnellSally P Wheatley
Dec 14, 2007·Nature Reviews. Cancer·Dario C Altieri
Sep 10, 2010·The Journal of Biological Chemistry·Haijuan WangRachel A Altura
May 4, 2011·Cellular Oncology (Dordrecht)·Anna G AntonacopoulouHaralabos P Kalofonos
Nov 8, 2013·Molecular Biology Reports·Romain BoidotSarab Lizard-Nacol

❮ Previous
Next ❯

Citations

Jan 22, 2015·Cell Cycle·Sally P Wheatley
May 1, 2015·Cell Cycle·Aysha M AljaberiSally P Wheatley
Apr 6, 2019·Journal of Cell Science·Sally P Wheatley, Dario C Altieri

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
Fluorescence
immunoprecipitation assay
acetylation
FACS
X-ray

Software Mentioned

DeltaVision
Volocity
Improvision
Adobe Photoshop
UCSF Chimera

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis